525 Ionic Liquid-Active Pharmaceutical Ingredient (IL-API) technologies provide several key benefits for pharmaceutical and drug delivery system makers. Each of these benefits can create new revenue opportunities for their current and next generation drug and drug delivery product pipelines by:

1. Enhancing drug performance      through ability to:

• tailor the drug’s performance and improve its capabilities
• better control over the drug’s time-release-rates
• reduce cost/time to develop new drug and delivery methods

2. Reducing drug development      failures through:

• better control over the effectiveness of the drug
• reductions of side effects and of toxicity issues
• elimination of polymorphic conversion issues
  

3. Extending a drug’s
     marketing lifetime
     through:

• life cycle management strategies to extend patent lifetime of blockbuster drugs
• offering a new composition of matter for every formulation.

525 will offer its technology and services to pharmaceutical and drug delivery system makers through strategic partnerships designed to address one or more of these issues over various development timelines.

The use of ionic liquids as a basis for the design, development, and delivery of pharmaceuticals is a revolutionary new method in drug design.

  Quick Facts:

  Market:
    Pharmaceuticals

  Market Size:
    $26.0B (2006)

  Market Potential:
    $121.4B (2014)

  Avg. cost of a failed drug:
    $868.0M

  Modified Drug Delivery
  Market:
    $39.8B (2009)

  Drugs scheduled to lose
  patent protection:
    $11.3B (2009)

  Team:
    Chief Operating Officer
        Jack Callaway

    Chief Technical Officer
        Dr. Rick Carliss

  Board of Advisors:
    Dr. Daniel T. Daly
    Director of AIME

    Dr. Robin D. Rogers
    Robert Ramsay Chair of
    Chemistry

    Larry Canada
    Galloway, Johnson,
    Tompkins, Burr & Smith

525 Products (IL-APIs) are unique combinations of different pharmaceuticals into liquid salts. Each of the pharmaceutical components has been carefully selected at the molecular level to deliver active pharmaceutical ingredients (APIs), vitamins or nutrients resulting in a multi-functional formulation.

Each IL has two components: at least one cation (having a net positive charge) and an at least one anion (having a net negative charge). An IL is formed when carefully engineered cation and anion are brought together to form a neutral, low melting salt. Because there are a plethora of possibilities with which to do so, choosing the correct pairs and combining them successfully requires substantial know-how.

525’S Resources have sizeable depth. Its Advisors have more than 35 years of cumulative experience in developing novel compounds and in using Ionic Liquids. They currently direct some of the world’s most prominent research teams in the general areas of IL research, design, and application. 525’s Principals have extensive experience in business development and bringing technologies and products to market. In addition, they have experience managing technology-based businesses in the US, Europe, and Asia, with revenues in excess of $75 million.

The University of Alabama
720 2nd Street
Tuscaloosa, AL 35401
205.348.3502
info@525solutions.com

© 2008 525 Solutions, Inc. All Rights Reserved.